Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

City of Hope has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the U.S. Department of Health and Human Services. The grant will help City of Hope create a biomap of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

FDA has approved Ibtrozi (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

June 13, 2025

Vol.51 No.23

Clinical

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Cancer Policy

Makary: Level of evidence is an artificial and dogmatic construct

Mehmet Oz, Robert F. Kennedy Jr., Marty Makary, Jayanta Bhattacharya, and Vinayak Prasad at an FDA Roundtable on Cell and Gene Therapy, June 5.Speaking at an FDA Roundtable on Cell and Gene Therapy, FDA Commissioner Marty Makary questioned the construct of “levels of evidence” as artificial and dogmatic, saying that n-of-1 “stories” can drive regulatory decisions.

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo

YOU MAY BE INTERESTED IN

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Makary: Level of evidence is an artificial and dogmatic construct

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo

YOU MAY BE INTERESTED IN

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

Makary: Level of evidence is an artificial and dogmatic construct

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats